This Article Free Full Text Free Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dominick, M. A. Articles by Schilling, B. E. Search for Related Content PubMed PubMed Citation Articles by Dominick, M. A. Articles by Schilling, B. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMMONIUM OXALATE CALCIUM COMPOUNDS CALCIUM, ELEMENTAL GLYCINE Medline Plus Health Information Bladder Cancer Social Bookmarking                         What's this?

Urothelial Carcinogenesis in the Urinary Bladder of Male Rats Treated with Muraglitazar, a PPAR/ Agonist: Evidence for Urolithiasis as the Inciting Event in the Mode of Action

¹ Department of Drug Safety Evaluation, Bristol-Myers Squibb Co., Evansville, Indiana 47721, USA
² Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA

Correspondence: Address correspondence to: Mark A. Dominick, 2400 W. Lloyd Expressway, P3, Evansville, IN 47721, USA; e-mail:mark.dominick{at}bms.com

Muraglitazar, a PPAR/ agonist, dose-dependently increased urinary bladder tumors in male Harlan Sprague–Dawley (HSD) rats administered 5, 30, or 50 mg/kg/day for up to 2 years. To determine the mode of tumor development, male HSD rats were treated daily for up to 21 months at doses of 0, 1, or 50 mg/kg while being fed either a normal or 1% NH₄Cl-acidified diet. Muraglitazar-associated, time-dependent changes in urine composition, urothelial mitogenesis and apoptosis, and urothelial morphology were assessed. In control and treated rats fed a normal diet, urine pH was generally 6.5, which facilitates formation of calcium- and magnesium-containing solids, particularly in the presence of other prolithogenic changes in rat urine. Urinary citrate, an inhibitor of lithogenesis, and soluble calcium concentrations were dose dependently decreased in association with increased calcium phosphate precipitate, crystals and/or microcalculi; magnesium ammonium phosphate crystals and aggregates; and calcium oxalate-containing thin, rod-like crystals. Morphologically, sustained urothelial cytotoxicity and proliferation with a ventral bladder predilection were noted in treated rats by month 1 and urinary carcinomas with a similar distribution occurred by month 9. Urothelial apoptotic rates were unaffected by muraglitazar treatment or diet. In muraglitazar-treated rats fed an acidified diet, urine pH was invariably < 6.5, which inhibited formation of calcium- and magnesium-containing solids. Moreover, dietary acidification prevented the urothelial cytotoxic, proliferative, and tumorigenic responses. Collectively, these data support an indirect pharmacologic mode of urinary bladder tumor development involving alterations in urine composition that predispose to urolithiasis and associated decreases in urine-soluble calcium concentrations.

Key Words: Dual PPAR/ agonist • urothelial • urinary bladder • carcinogenesis • urolithiasis • hypocalciuria

Abbreviations: AGT, alanine glyoxalate aminotransferase • AUC, area under the curve • BrdU, aromodeoxyuridine • C-DIM, 1, 1-bis (3'-indolyl)-1-(p-substituted phenyl) methanes • dUTP, aeoxyuridine triphosphate • EGF, epidermal growth factor • FDA, Federal Drug Administration • GAO, glycolate oxidase • HSD, Harlan Sprague–Dawley • IP, intraperitoneal • LDH, lactate dehydrogenase • mRNA, messenger ribonucleic acid • NaDC-1, sodium dicarboxylate cotransporter • NCI, National Cancer Institute • PEG, polyethylene glycol • PPAR, peroxisome proliferator activated receptor • PPRE, peroxisome proliferator response element • RXR, retinoid X receptor • SD, standard deviation • SD rats, Sprague-Dawley rats • SEM, scanning electronic microscopy • TCA, tricarboxylic acid • THP, Tamm-Horsfall protein • TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling • XDS, energy dispersive X-ray spectroscopy

Toxicologic Pathology, Vol. 34, No. 7, 903-920 (2006)
DOI: 10.1080/01926230601072327


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. G. Long, V. L. Reynolds, L. W. Dochterman, and T. E. Ryan Neoplastic and Non-neoplastic Changes in F-344 Rats Treated with Naveglitazar, a {gamma}-Dominant PPAR {alpha}/{gamma} Agonist Toxicol Pathol, October 1, 2009; 37(6): 741 - 753. [Abstract] [Full Text] [PDF]

				S. H. Tannehill-Gregg, M. A. Dominick, A. J. Reisinger, J. D. Moehlenkamp, C. R. Waites, D. A. Stock, T. P. Sanderson, S. M. Cohen, L. L. Arnold, and B. E. Schilling Strain-related Differences in Urine Composition of Male Rats of Potential Relevance to Urolithiasis Toxicol Pathol, April 1, 2009; 37(3): 293 - 305. [Abstract] [Full Text] [PDF]

				F. Ondrey Peroxisome Proliferator-Activated Receptor {gamma} Pathway Targeting in Carcinogenesis: Implications for Chemoprevention Clin. Cancer Res., January 1, 2009; 15(1): 2 - 8. [Abstract] [Full Text] [PDF]

				B. Chopra, J. Hinley, M. B. Oleksiewicz, and J. Southgate Trans-Species Comparison of PPAR and RXR Expression by Rat and Human Urothelial Tissues Toxicol Pathol, April 1, 2008; 36(3): 485 - 495. [Abstract] [Full Text] [PDF]

				G. G. Long, V. L. Reynolds, A. Lopez-Martinez, T. E. Ryan, S. L. White, and S. R. Eldridge Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a {gamma}-dominant PPAR {alpha}/{gamma} Agonist: Lack of Evidence for Urolithiasis as an Inciting Event Toxicol Pathol, February 1, 2008; 36(2): 218 - 231. [Abstract] [Full Text] [PDF]

				T. Ohnishi, L. L. Arnold, N. M. Clark, J. L. Wisecarver, and S. M. Cohen Comparison of Endothelial Cell Proliferation in Normal Liver and Adipose Tissue in B6C3F1 Mice, F344 Rats, and Humans Toxicol Pathol, December 1, 2007; 35(7): 904 - 909. [Abstract] [Full Text] [PDF]

				S. M. Cohen, T. Ohnishi, N. M. Clark, J. He, and L. L. Arnold Investigations of Rodent Urinary Bladder Carcinogens: Collection, Processing, and Evaluation of Urine and Bladders Toxicol Pathol, April 1, 2007; 35(3): 337 - 347. [Abstract] [Full Text] [PDF]